April 25, 2025

Cinnamon Oil May Trigger Drug Interactions

Cinnamaldehyde may modestly activate drug-metabolizing receptors, raising potential herb–drug interaction concerns.

Conexiant

April 24, 2025

Large Trial Finds No Stroke Benefit From CEP, Study

A large U.K. trial found that routine use of cerebral embolic protection did not decrease the incidence of stroke within 72 hours among patients undergoing TAVI.

Conexiant

April 24, 2025

Microplastics: Potential Contributor to Carotid Atherosclerosis?

New research links high levels of micronanoplastics in carotid artery plaque to stroke symptoms, suggesting a potential new target for cardiovascular disease prevention.

Conexiant

April 24, 2025

Karen E. Knudsen, MBA, PhD, Appointed Chief Executive Officer of the Parker Institute for Cancer Immunotherapy

The Parker Institute for Cancer Immunotherapy (PICI) announced the appointment of Karen E. Knudsen, MBA, PhD, as its new Chief Executive Officer (CEO). A visionary leader in oncology, health-care deli...

The ASCO Post

April 24, 2025

WHI Funding Cuts Threaten Research Continuity

HHS will terminate WHI Regional Center funding in September 2025.

Conexiant

April 23, 2025

Sense of Belonging 'Critical' for Workplace Retention

Individuals who reported a neutral level of satisfaction with their sense of belonging were approximately 3 times more likely to express an intent to leave, while those who were dissatisfied were 7 times more likely to do so, compared to individuals who were satisfied with their sense of belonging.

Conexiant

April 23, 2025

Life's Essential 8 Helps Predict CVD

"Greater cumulative CVH and improvement in CVH during young adulthood, as well as better CVH in middle age, were all independently associated with lower risk for incident CVD in midlife."

Conexiant

April 22, 2025

AHA Framework Maps HF Prevention Strategy

“The growing morbidity, mortality, and health care costs related to heart failure underscore the urgent need to prioritize its primary prevention.”

Conexiant

April 22, 2025

Extended Follow-up of Belzutifan Treatment for von Hippel–Lindau Disease–Associated Renal Cell Carcinoma

In extended follow-up of the phase II LITESPARK-004 trial reported in The Lancet Oncology, Srinivasan et al looked at the use of belzutifan and outcomes in patients with von Hippel–Lindau disease-asso...

The ASCO Post